Breakthrough in Treating Schizophrenia
A significant study from Israeli researchers has introduced a new deep brain stimulation technique aimed at aiding individuals with schizophrenia. This innovative therapy could potentially restore vital functions related to movement, learning, and decision-making for those affected by this chronic mental disorder.
Dr. Nir Asch, a leading researcher at Rambam Health Care Campus in Haifa, commented on the study’s implications, suggesting it paves the way for additional treatment options for patients who haven’t seen improvement from current therapies.
The research, which utilized computational modeling and machine learning, was published in the journal Nature Communications. It was conducted under the mentorship of Prof. Hagai Bergman, an esteemed neuroscientist at the Hebrew University of Jerusalem known for his groundbreaking work in deep brain stimulation (DBS), particularly for Parkinson’s disease.
Dr. Asch pointed out that many psychiatric disorders are often identified merely by their symptoms. “Our paper gives a clear theoretical framework regarding the mechanical processes in the brain, along with solutions,” he explained during an interview.
Currently, approximately 70,000 individuals in Israel grapple with schizophrenia, which translates to about one in every 143 residents, according to information from the mental health organization Ozma.
Dr. Asch raised an important question: “Why should we care about schizophrenia?” He then provided a sobering statistic—about 21 million people worldwide live with the disorder, with around a third resistant to treatment. He emphasized that this is a considerable global challenge.
The Impact of Schizophrenia
Typically emerging in the early 20s, schizophrenia is a severe disorder that can lead to lifelong challenges. Symptoms often include hallucinations—people seeing or hearing things that aren’t there—and persistent delusions, where individuals cling to false beliefs.
Other characteristics of the disorder encompass disorganized thought and speech, unusual behavior, and social withdrawal. These aspects greatly hinder functional abilities and can cause both social and familial stigma. Moreover, cognitive functions, including memory and attention, are often compromised, complicating daily decision-making.
According to the World Health Organization, individuals with schizophrenia have a shorter lifespan, dying approximately nine years earlier than the general population, often due to secondary health issues like diabetes.
To understand schizophrenia better, Dr. Asch remarked that one must first grasp the brain’s operational mechanics.
“Essentially, the brain acts as a prediction machine,” Asch explained. It constructs models of reality, asking questions about circumstances in its environment and adjusting based on sensory input.
In patients with schizophrenia, this predictive mechanism falters. They often experience “cognitive inflexibility,” making it challenging to adapt their mental models when there are changes in the environment.
Exploring Brain Networks
As part of the study, Asch and his team examined the effects of DBS on two female African green monkeys. In a controlled lab situation, these monkeys were administered phencyclidine (PCP), a drug known to induce psychotic states similar to those seen in schizophrenia.
As a result, their cognitive flexibility diminished, and erratic behaviors increased. The researchers thus targeted the globus pallidus externus (GPe), a brain region essential for decision-making.
The GPe is part of a network involving the basal ganglia and the dorsolateral prefrontal cortex (DLPFC), which collaborates to govern habits and choice-making.
Transformative Results
The GPe functions like a dynamic filter within this neuronal network. Disruption in this area can lead to confused thought processes. However, upon applying low-frequency DBS, noticeable improvements were quickly observed.
“Cognitive inflexibility was cured,” Asch stated, noting that the monkeys returned to healthy cognitive levels and exhibited less chaotic behavior.
This hypothesis stemmed from findings that certain brain stimulation techniques could alleviate Parkinson’s symptoms. Dr. Asch credited Prof. Bergman as a preeminent figure in the field of DBS.
Looking Ahead
Dr. Idit Tamir, a functional neurosurgery director at Rabin Medical Center, highlighted the importance of cognitive flexibility in everyday decisions. She mentioned that similar improvements are already observable in various patient populations receiving DBS.
The research team is now preparing to transition to human clinical trials, buoyed by the promising results in primates. Dr. Asch expressed that his recent experiences treating patients have shifted his motivations, emphasizing the need for effective treatment options for those suffering.
He added, “It can be incredibly disheartening as a physician when effective treatments are scarce. Introducing effective tools for recovery would truly be remarkable.”
